dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV RNA-dependent RNA polymerase

Ligand: VV116 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: China NMPA (2023)
Primary target: no
Median affinity:  -
Reference (Journal): Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2.
Published in: Cell Res

Ligand: V2043 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: remdesivir (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA & EMA (2020)
Primary target: no
Median affinity:  -
Reference (Journal): Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Published in: J Biol Chem

Ligand: remdesivir (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA & EMA (2020)
Primary target: no
Median affinity:  -
Reference (Journal): Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Published in: J Biol Chem

Ligand: obeldesivir (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.
Published in: Bioorg Med Chem

Ligand: GS-621763 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
Published in: bioRxiv
Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV Non-structural protein 15

Ligand: tipiracil (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Japan only
Primary target: no
Median affinity:  -
Reference (Journal): Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2.
Published in: Commun Biol
Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV Non-structural protein 14

Ligand: TO507 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors.
Published in: ACS Infect Dis

Ligand: TO507 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pKd
Reference (Journal): The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors.
Published in: ACS Infect Dis

Ligand: compound 25 [PMID: 35439007] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Potent Inhibition of SARS-CoV-2 nsp14 <i>N</i>7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues.
Published in: J Med Chem

Ligand: '9213 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.699999809265137 pIC50
Reference (Journal): Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase
Published in: J Med Chem

Ligand: '2882 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.21999979019165 pIC50
Reference (Journal): Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase
Published in: J Med Chem

Ligand: '1988 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.659999847412109 pIC50
Reference (Journal): Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase
Published in: J Med Chem
Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV Non-structural protein 13

Ligand: compound 4b [Ramsey et al., 2023] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.239999771118164 pIC50
Reference (Journal): Using a Function-First "Scout Fragment"-Based Approach to Develop Allosteric Covalent Inhibitors of Conformationally Dynamic Helicase Mechanoenzymes.
Published in: J Am Chem Soc

Ligand: compound 1b [PMID: 37562607] (Synthetic organic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.329999923706055 pIC50
Reference (Journal): Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
Published in: Antiviral Res

Ligand: compound 1b [PMID: 37562607] (Synthetic organic)
Interaction type: Allosteric modulator
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.090000152587891 pIC50
Reference (Journal): Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
Published in: Antiviral Res

Ligand: compound 16 [PMID: 31955138] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors.
Published in: Acta Pharm
Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV Envelope protein

Ligand: iPep-SARS2-E (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Developing inhibitory peptides against SARS-CoV-2 envelope protein.
Published in: PLoS Biol
Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV 2'-O-methyltransferase

Ligand: RS-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.880000114440918 pIC50
Reference (Journal): Informatics and Computational Approaches for the Discovery and Optimization of Natural Product-Inspired Inhibitors of the SARS-CoV-2 2'-<i>O</i>-Methyltransferase.
Published in: J Nat Prod

Ligand: RS-2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.869999885559082 pIC50
Reference (Journal): Informatics and Computational Approaches for the Discovery and Optimization of Natural Product-Inspired Inhibitors of the SARS-CoV-2 2'-<i>O</i>-Methyltransferase.
Published in: J Nat Prod

Ligand: sinefungin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.46999979019165 pIC50
Reference (Journal): A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex.
Published in: SLAS Discov
Target family: CRK7 subfamily (type: enzyme)
Target: cyclin dependent kinase 12

Ligand: CDK12 inhibitor 2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.28000020980835 pIC50
Reference (Journal): Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Published in: J Med Chem

Ligand: SY-5609 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.769999980926514 pIC50
Reference (Journal): Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.
Published in: J Med Chem
Target family: CRK7 subfamily (type: enzyme)
Target: cyclin dependent kinase 13

Ligand: CDK12 inhibitor 2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Published in: J Med Chem
Target family: Csk family (type: enzyme)
Target: C-terminal Src kinase

Ligand: NG-25 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.25 pIC50
Reference (Journal): Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2).
Published in: J Med Chem

Ligand: PP1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.28000020980835 pIC50
Reference (Journal): The specificities of protein kinase inhibitors: an update.
Published in: Biochem J

Ligand: rivoceranib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: 2014 (Chinese NMPA)
Primary target: no
Median affinity: 6.28000020980835 pIC50
Reference (Journal): YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
Published in: Cancer Sci
Target family: C-type lectin-like receptors (CLRs) (type: other_protein)
Target: C-type lectin domain family 12 member A

Ligand: tepoditamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pKd
Reference (Journal): Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML
Published in: Blood
Target family: C-type lectin-like receptors (CLRs) (type: other_protein)
Target: C-type lectin domain family 4 member C

Ligand: litifilimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
Published in: J Clin Invest
Target family: C-type lectin-like receptors (CLRs) (type: other_protein)
Target: C-type lectin domain family 4 member E

Ligand: GlcC14C18 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10 pEC50
Reference (Journal): Rational design of adjuvants targeting the C-type lectin Mincle.
Published in: Proc Natl Acad Sci USA
Target family: Cyclic GMP-AMP synthase (type: enzyme)
Target: Cyclic GMP-AMP synthase

Ligand: baicalin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.960000038146973 pIC50
Reference (Journal): Discovery of novel cGAS inhibitors based on natural flavonoids.
Published in: Bioorg Chem

Ligand: baicalin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pIC50
Reference (Journal): Discovery of novel cGAS inhibitors based on natural flavonoids.
Published in: Bioorg Chem

Ligand: compound 20 [PMID: 37666112] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.639999866485596 pIC50
Reference (Journal): Discovery of novel cGAS inhibitors based on natural flavonoids.
Published in: Bioorg Chem

Ligand: compound 20 [PMID: 37666112] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.840000152587891 pIC50
Reference (Journal): Discovery of novel cGAS inhibitors based on natural flavonoids.
Published in: Bioorg Chem

Ligand: PF‐06928215 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pKd
Reference (Journal): Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay.
Published in: PLoS One

Ligand: PF‐06928215 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.309999942779541 pIC50
Reference (Journal): Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay.
Published in: PLoS One
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: HCN1

Ligand: propofol (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1989)
Median affinity: 5.2 pIC50
Reference (Journal): Propofol inhibits HCN1 pacemaker channels by selective association with the closed states of the membrane embedded channel core.
Published in: J Physiol (Lond.)

Ligand: zatebradine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): Bradycardic and proarrhythmic properties of sinus node inhibitors.
Published in: Mol Pharmacol

Ligand: ZD7288 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.699999809265137 pIC50
Reference (Journal): Functional expression of the human HCN3 channel.
Published in: J Biol Chem
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: HCN3

Ligand: cilobradine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): Bradycardic and proarrhythmic properties of sinus node inhibitors.
Published in: Mol Pharmacol

Ligand: Cs+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 3.799999952316284 pIC50
Reference (Journal): Functional expression of the human HCN3 channel.
Published in: J Biol Chem

Ligand: ivabradine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: EMA (2005), FDA (2015)
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Bradycardic and proarrhythmic properties of sinus node inhibitors.
Published in: Mol Pharmacol

Ligand: zatebradine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): Bradycardic and proarrhythmic properties of sinus node inhibitors.
Published in: Mol Pharmacol

Ligand: ZD7288 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.5 pIC50
Reference (Journal): Functional expression of the human HCN3 channel.
Published in: J Biol Chem
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: HCN4

Ligand: cilobradine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): Bradycardic and proarrhythmic properties of sinus node inhibitors.
Published in: Mol Pharmacol

Ligand: clonidine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 5.010000228881836 pIC50
Reference (Journal): Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine.
Published in: Circulation

Ligand: Cs+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 3.799999952316284 pIC50
Reference (Journal): Functional expression of the human HCN3 channel.
Published in: J Biol Chem

Ligand: EC18 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pEC50
Reference (Journal): Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue.
Published in: Br J Pharmacol
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: HCN1

Ligand: MEL57A (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.489999771118164 pEC50
Reference (Journal): Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue.
Published in: Br J Pharmacol
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: HCN4

Ligand: MEL57A (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 4.119999885559082 pEC50
Reference (Journal): Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue.
Published in: Br J Pharmacol

Ligand: zatebradine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): Bradycardic and proarrhythmic properties of sinus node inhibitors.
Published in: Mol Pharmacol

Ligand: ZD7288 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.699999809265137 pIC50
Reference (Journal): Functional expression of the human HCN3 channel.
Published in: J Biol Chem

Ligand: ivabradine (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: EMA (2005), FDA (2015)
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Bradycardic and proarrhythmic properties of sinus node inhibitors.
Published in: Mol Pharmacol
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: HCN1

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 3.3 pIC50
Reference (Journal): Intracellular Mg2+ is a voltage-dependent pore blocker of HCN channels.
Published in: Am J Physiol, Cell Physiol

Ligand: propofol (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1989)
Median affinity: 5.2 pIC50
Reference (Journal): Impairment of hyperpolarization-activated, cyclic nucleotide-gated channel function by the intravenous general anesthetic propofol.
Published in: J Pharmacol Exp Ther
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: CNGA1

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Functional co-assembly among subunits of cyclic-nucleotide-activated, nonselective cation channels, and across species from nematode to human.
Published in: Biophys J

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): A histidine residue associated with the gate of the cyclic nucleotide-activated channels in rod photoreceptors.
Published in: Neuron

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Subunit 2 (or beta) of retinal rod cGMP-gated cation channel is a component of the 240-kDa channel-associated protein and mediates Ca(2+)-calmodulin modulation.
Published in: Proc Natl Acad Sci USA

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Rod cyclic nucleotide-gated channels have a stoichiometry of three CNGA1 subunits and one CNGB1 subunit.
Published in: Neuron

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Human rod photoreceptor cGMP-gated channel: amino acid sequence, gene structure, and functional expression.
Published in: J Neurosci

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa.
Published in: Proc Natl Acad Sci USA

Ligand: dequalinium (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Dequalinium: a novel, high-affinity blocker of CNGA1 channels.
Published in: J Gen Physiol

Ligand: H-8 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 3.5 pIC50
Reference (Journal): Direct blockade of both cloned rat rod photoreceptor cyclic nucleotide-gated non-selective cation (CNG) channel alpha-subunit and native CNG channels from Xenopus rod outer segments by H-8, a non-specific cyclic nucleotide-dependent protein kinase inhibitor.
Published in: Neurosci Lett

Ligand: L-(cis)-diltiazem (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4 pKi
Reference (Journal): A new subunit of the cyclic nucleotide-gated cation channel in retinal rods.
Published in: Nature
Target family: Cyclic nucleotide-regulated channels (CNG) (type: vgic)
Target: CNGA3

Ligand: cyclic AMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity: 3.6 pKd
Reference (Journal): Electrophysiological characteristics of rat gustatory cyclic nucleotide--gated channel expressed in Xenopus oocytes.
Published in: J Neurophysiol

Ligand: cyclic AMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity: 2.88 pKd
Reference (Journal): Molecular cloning, functional expression and chromosomal localization of a human homolog of the cyclic nucleotide-gated ion channel of retinal cone photoreceptors.
Published in: FEBS Lett

Ligand: cyclic AMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity: 2.88 pKd
Reference (Journal): Functionally important calmodulin-binding sites in both NH2- and COOH-terminal regions of the cone photoreceptor cyclic nucleotide-gated channel CNGB3 subunit.
Published in: J Biol Chem

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Cloning, chromosomal localization and functional expression of the gene encoding the alpha-subunit of the cGMP-gated channel in human cone photoreceptors.
Published in: Eur J Neurosci

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Functionally important calmodulin-binding sites in both NH2- and COOH-terminal regions of the cone photoreceptor cyclic nucleotide-gated channel CNGB3 subunit.
Published in: J Biol Chem

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Molecular cloning, functional expression and chromosomal localization of a human homolog of the cyclic nucleotide-gated ion channel of retinal cone photoreceptors.
Published in: FEBS Lett

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.510000228881836 pKd
Reference (Journal): Electrophysiological characteristics of rat gustatory cyclic nucleotide--gated channel expressed in Xenopus oocytes.
Published in: J Neurophysiol

Ligand: L-(cis)-diltiazem (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -